

RULES AND DIRECTIVES
BRANCH
USNRC

2017
2016 JUN 23 AM 7:49

PUBLIC SUBMISSION

As of: 6/22/17 5:02 PM
Received: June 15, 2017
Status: Pending Post
Tracking No. 1k1-8wz0-irh8
Comments Due: June 27, 2017
Submission Type: Web

RECEIVED

Docket: NRC-2017-0094
Patient Release Program

Comment On: NRC-2017-0094-0004
Patient Release Program; Extension of Comment Period

Document: NRC-2017-0094-DRAFT-0019
Comment on FR Doc # 2017-11027

82 FR 17465

4/11/2017

33

Submitter Information

Name: Kellee Ferry
Address:
1234 Napier Ave.
St. Joseph, MI, 49085
Email: kferry@lakelandhealth.org
Submitter's Representative: James Carey
Organization: Medical Physics

General Comment

Date: 6/15/17

Cindy Bladey, Office of Administration

RE: Response to NRC Request for Comment NRC Docket ID NRC20170094

I am a Lead Nuclear Medicine Technologist at a medical facility licensed by the USNRC, State of Michigan.

I am submitting this letter in support of the Comment Response Letter submitted by James Carey, Medical Physics

SUNSI Review Complete
Template = ADM - 013
E-RIDS= ADM-03

Add= D.B. Howe (DBH)

C. Rasapa K&E (CJR2)

Consultants, Inc. dated June 9, 2017. I have reviewed this response letter and agree with the contents.

Please accept my response to the request for comments NRC Docket ID NRC20170094.

Additionally, I am in strong belief that it is the responsibility of each licensed site to access iodine therapy patients on a case-by-case basis.

We have an required consult practice at our site(s) to address each individual's ability/intent of compliance/adherence to ALARA practices prior to therapy.

During this consult, the Licensed Radiation Oncologist or Radiologist, Nuclear Medicine Technologist, and patient assess the practices/timeframe required for procedure to be done on an outpatient basis.

If the doctor and/or Nuclear Medicine Technologist deems the patient incapable or unwilling to follow these practices, the therapy is then scheduled to be done in-house until exposure levels reach the "safe" level for discharge per regulatory guidelines.

Thank you for the opportunity to participate in this process.

Respectfully Submitted,

Kellee Ferry, CNMT/RT(N)